Efrat Flashner-Abramson
Hebrew University of Jerusalem
16 Papers
77 Citations
Efrat Flashner-Abramson is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 8, co-authored 14 publications.
Chat about Author
Papers
Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
Efrat Flashner-Abramson,Shoshana Klein,G Mullin,E Shoshan,Renduo Song,Alexei Shir,Yael Langut,Menashe Bar-Eli,Hadas Reuveni,Alexander Levitzki +9 more
TL;DR: The previous study of the novel compound, NT157, is expanded, and it is shown that it acts as a dual-targeting agent that invokes the blockage of two signal transduction pathways that are central to the development and maintenance of multiple human cancers.
41
Personalized disease signatures through information-theoretic compaction of big cancer data
Swetha Vasudevan,Efrat Flashner-Abramson,Françoise Remacle,Françoise Remacle,Raphael D. Levine,Raphael D. Levine,Nataly Kravchenko-Balasha +6 more
TL;DR: It is shown that different patients may display similar oncogene expression levels, albeit carrying biologically distinct tumors that harbor different sets of unbalanced molecular processes, which highlights the need to expand the notion of tumor-specific oncogenic biomarkers to patient-specific, comprehensive transcriptional networks for improved patient-tailored diagnostics.
23
Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Shih-Ping Su,Efrat Flashner-Abramson,Shoshana Klein,Mor Gal,Rachel S. Lee,Jianmin Wu,Alexander Levitzki,Roger J. Daly +7 more
TL;DR: Mass spectrometry–based global tyrosine phosphorylation profiling of NT157-treated A375 melanoma cells provides novel insights into NT157 action on cancer cells and highlights how globally profiling the impact of a specific drug on cellular signaling networks can identify effective combination treatments.
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations.
Swetha Vasudevan,Efrat Flashner-Abramson,Heba Alkhatib,Sangita Roy Chowdhury,Ibukun Adesoji Adejumobi,D Vilenski,Shira Stefansky,A M Rubinstein,Nataly Kravchenko-Balasha +8 more
- 10 Jun 2021
TL;DR: In this article, the authors proposed an information-theoretic approach to compute high-resolution patient-specific altered signaling signatures, which should all be targeted to optimally inhibit the entire altered signaling flux.
Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
H. Alkhatib,Ariel Rubinstein,Swetha Vasudevan,Efrat Flashner-Abramson,Shira Stefansky,Sangita Roy Chowdhury,S. Oguche,Tamar Peretz-Yablonsky,Avital Granit,Zvi Granot,Ittai Ben-Porath,K. Sheva,Jon Feldman,Noa E. Cohen,Amichay Meirovitz,Nataly Kravchenko-Balasha +15 more
TL;DR: In this article , a single-cell quantification strategy was developed to provide a high-resolution and individualized assessment of tumor composition for a customized treatment approach, which was validated using TNBC models and patient-derived tumors known to switch phenotypes in response to radiotherapy (RT).